Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2025)

ARS Pharmaceuticals' Retained Earnings history spans 5 years, with the latest figure at -$294.6 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 138.92% year-over-year to -$294.6 million; the TTM value through Dec 2025 reached -$294.6 million, down 138.92%, while the annual FY2025 figure was -$294.6 million, 138.92% down from the prior year.
  • Retained Earnings for Q4 2025 was -$294.6 million at ARS Pharmaceuticals, down from -$253.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $339000.0 in Q3 2024 and bottomed at -$294.6 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$76.9 million (2022), against an average of -$91.5 million.
  • The largest YoY upside for Retained Earnings was 310.56% in 2024 against a maximum downside of 251742.86% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$162.8 million in 2021, then soared by 52.74% to -$76.9 million in 2022, then soared by 100.06% to $49000.0 in 2023, then tumbled by 251742.86% to -$123.3 million in 2024, then crashed by 138.92% to -$294.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Retained Earnings are -$294.6 million (Q4 2025), -$253.3 million (Q3 2025), and -$46000.0 (Q2 2025).